文献速递前列腺癌男科与性医学

前列腺癌放疗中的性结构保护:一项系统综述

Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic Review.
PubMed 文献 · Eur Urol Oncol · 2023-08-26

本系统综述检索PubMed与ClinicalTrials.gov至2023年1月4日,评估性结构剂量-体积参数与勃起功能障碍发生的关系及性结构保护技术的可行性。结果显示阴茎球部平均剂量超过20 Gy可预测勃起功能障碍,保持阴部内动脉D100%≤36 Gy在5年时88%患者保留勃起功能,神经血管束保护在磁共振引导放疗下技术可行但临床影响未知,睾丸剂量通常<2 Gy使睾酮下降4.6%至17%。

要点

  • 阴茎球部平均剂量超过20 Gy可预测现代前列腺癌放疗试验中的勃起功能障碍。
  • 阴部内动脉D100%≤36 Gy时,5年时88%患者保留勃起功能。
  • 磁共振引导放疗下神经血管束保护技术可行,但临床影响尚未明确。

核心结论

  • 当前数据表明前列腺癌放疗中的性结构保护在技术上是可行的。
  • 性结构所受剂量导致的勃起功能障碍比例仍很大程度上未知。
  • 性功能维持受年龄或合并症等因素影响,仅部分选定患者可能从性保护放疗中获益。

研究设计与样本

  • 系统综述,检索PubMed数据库和ClinicalTrials.gov至2023年1月4日。
  • 纳入报告性结构剂量对性功能影响或创新性结构保护方法可行性的研究。

主要发现

  • 阴茎球部平均剂量超过20 Gy可预测现代前列腺癌放疗试验中的勃起功能障碍。
  • 保持阴部内动脉D100%≤36 Gy时,5年时88%患者保留勃起功能。
  • 磁共振引导放疗下神经血管束保护技术可行,但临床影响尚未明确。
  • 前列腺癌放疗期间睾丸剂量通常<2 Gy,导致睾酮水平下降4.6%至17%,不太可能产生临床影响。

关键数值与推荐

  • 阴茎球部平均剂量超过20 Gy为勃起功能障碍的预测指标。
  • 阴部内动脉D100%≤36 Gy与5年时88%患者保留勃起功能相关。
  • 睾丸剂量通常<2 Gy,睾酮水平下降4.6%至17%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 性结构所受剂量导致的勃起功能障碍比例仍很大程度上未知。
  • 性功能维持受年龄或合并症等因素影响,仅部分选定患者可能从性保护放疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Erectile dysfunction represents a major side effect of prostate cancer (PCa) treatment, negatively impacting men's quality of life. While radiation therapy (RT) advances have enabled the mitigation of both genitourinary and gastrointestinal toxicities, no significant improvement has been showed in sexual quality of life over time. OBJECTIVE: The primary aim of this review was to assess sexual structures' dose-volume parameters associated with the onset of erectile dysfunction. EVIDENCE ACQUISITION: We searched the PubMed database and ClinicalTrials.gov until January 4, 2023. Studies reporting the impact of the dose delivered to sexual structures on sexual function or the feasibility of innovative sexual structure-sparing approaches were deemed eligible. EVIDENCE SYNTHESIS: Sexual-sparing strategies have involved four sexual organs. The mean penile bulb doses exceeding 20 Gy are predictive of erectile dysfunction in modern PCa RT trial. Maintaining a D100% of ≤36 Gy on the internal pudendal arteries showed preservation of erectile function in 88% of patients at 5 yr. Neurovascular bundle sparing appears feasible with magnetic resonance-guided radiation therapy, yet its clinical impact remains unanswered. Doses delivered to the testicles during PCa RT usually remain <2 Gy and generate a decrease in testosterone levels ranging from -4.6% to -17%, unlikely to have any clinical impact. CONCLUSIONS: Current data highlight the technical feasibility of sexual sparing for PCa RT. The proportion of erectile dysfunction attributable to the dose delivered to sexual structures is still largely unknown. While the ability to maintain sexual function over time is impacted by factors such as age or comorbidities, only selected patients are likely to benefit from sexual-sparing RT. PATIENT SUMMARY: Technical advances in radiation therapy (RT) made it possible to significantly lower the dose delivered to sexual structures. While sexual function is known to decline with age, the preservation of sexual structures for prostate cancer RT is likely to be beneficial only in selected patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Le Guevelou J, Sargos P, Ferretti L, et al. Sexual Structure Sparing for Prostate Cancer Radiotherapy: A Systematic Review. Eur Urol Oncol. 2023. PMID: 37640583. doi:10.1016/j.euo.2023.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。